Clinical trial · Interventional
Role of Neutrophils and Electro-bioluminescence in the Rehabilitation
Role of Neutrophils and Electro-bioluminescence in the Therapeutic Stage of Medical Rehabilitation of Some Oncologic Diseases (Pilot Project)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The clinical study is to find out the effect of a course of immunomodulatory drugs and detoxification scheme on finger bioelectroluminescence and neutrophil function and their correlation with changes in quality of life and life expectancy in patients with malignant diseases against the background of restorative treatment and rehabilitation. Questions: 1. does the quality of life of patients with lung cancer change with the use of a course of immunomodulatory drugs and detoxification scheme? 2. does phagocytosis function, liposomal activity, mitochondrial function of neutrophils change against the background of the course? 3. does bioluminescence of fingers of hands change against the background of the course of immunotherapy? Participants will take Calcitreol capsules, Magnesium B-6 capsules, products containing quercetin flavonoids, Naderin (sodium deoxeribonucleate) daily for 21 days. before the course, after the course and after one year they will answer the QLQ-LC13, WHOQOL BREF, L.H. Garkavi adaptation self-assessment questionnaire and give blood for laboratory analysis of neutrophil function assessment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nonsmall-cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| sodium nucleinate | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- natirium nucleonate
- description
- * Calcitriol- 5000 units in the morning before meals every other day 21 days and the next 3 weeks after the end of therapy. * Magnesium (in the form of lactate dihydrate) 470 mg + pyridoxine (in the form of hydrochloride) 5 mg - take orally 3 tablets per meter square of body surface area, in the evening 2 hours before bedtime, 21 days and the next 3 weeks after the end of therapy. * Quercetin from onion juice - take orally 1000 mg in the morning before meals, 21 days, as well as the next 3 weeks after the end of therapy. * sodium oligodinucleatide orally at the rate of 2 tablets under the tongue per meter square of body surface, in the morning 15 minutes before meals every other day, a total of 5 times (1, 3, 5, 7 , 9 day from the beginning of therapy), then after 21 days to repeat the course for 3 months. * Spray natirium nucleonate 4 doses in the morning on the hyoid, suck, do not swallow for 3-5 minutes, once every 4 days for 21 days.
- interventionNames
- Biological: sodium nucleinate
Primary outcomes (3)
- measure
- scoring of completed quality-of-life tests
- timeFrame
- Before the start of the intervention, on day 22 after the start of the intervention, and after 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis Non-small cell lung cancer (histologically verified) * Must be able to swallow tablets * Detected for the first time * Presence of all fingers and toes * Patient must give their informed and signed consent * Patient must be insured or have a health insurance plan. * Clinically stable patients regardless of disease type. * Absence of cognitive impairment; since the protocol provides for a clinical interview covering in particular his/her quality of life Exclusion Criteria: * Decompensated forms of cancer (decompensation statuses of vital organs (pulmonary, cardiac, hepatic, renal, intestinal insufficiency); * Clinical diagnosis other types of cancer, secondary tumors and lung metastases; * Postoperative condition for lung tumor resection; * Patient belongs to a vulnerable group; * Patients with severe cognitive impairment; * Tuberculosis of any localization in the active phase and in the anamnesis; * Severe and decompensated course of endocrine diseases, including diabetes mellitus; * Autoimmune diseases; * Pregnancy and lactation period; * Prisoners; * Active military personnel; * People without education; * pensioners; * People living below the poverty line or with limited access to health services. * Unwillingness to participate in the study. * Patient is participating in another study * Patient with inability to complete our protocol evaluation scales * Patients with symptoms that compromise their level of awareness * Insulin dependent diabetes * Thyroid disease
References
Publications (0)
Data not yet available